Aravive to Present Late-Breaking Oral Presentation at European Society for Medical Oncology Congress 2019 in Barcelona
September 18 2019 - 7:00AM
Aravive, Inc. (Nasdaq: ARAV) today announced that its late-breaking
abstract has been accepted for oral presentation in a proffered
paper session at the European Society for Medical Oncology (ESMO)
Congress 2019 in Barcelona.
The abstract (ID 6602), titled “Phase 1b/2 Study of AVB500 (High
Affinity Inhibitor of GAS6/AXL Path) in Combination with PAC and
PLD in Platinum Resistant Recurrent Ovarian Cancer,” will be
presented at 4:15 p.m. local time (10:15 a.m. ET) on Friday, Sept.
27 in the Pamplona Auditorium (Hall 2) at Fira Gran Via. The data
will be presented by lead investigator of the study, Bradley J.
Monk, M.D., professor and director of the division of gynecologic
oncology at Creighton University School of Medicine at St. Joseph’s
Hospital and Medical Center in Phoenix, Arizona.
Aravive previously announced topline efficacy data from this
study showing compelling anti-tumor activity in the first 12
patients.
About Aravive Aravive, Inc. (Nasdaq:
ARAV) is a clinical-stage biopharmaceutical company developing
treatments designed to halt the progression of life-threatening
diseases, including cancer and fibrosis. Aravive’s lead product
candidate, AVB-500, is an ultra-high affinity decoy protein that
targets the GAS6-AXL signaling pathway. By capturing serum GAS6,
AVB-500 starves the AXL pathway of its signal, potentially halting
the biological programming that promotes disease progression. AXL
receptor signaling plays an important role in multiple types of
malignancies by promoting metastasis, cancer cell survival,
resistance to treatments, and immune suppression. The GAS6-AXL
signaling pathway also plays a significant role in
fibrogenesis. Aravive is evaluating AVB-500 in
platinum-resistant ovarian cancer, and intends to expand
development into additional oncology and fibrotic
indications. Aravive is based in Houston,
Texas and received a Product Development Award from
the Cancer Prevention & Research Institute of
Texas (CPRIT) in 2016. Aravive was one of
FierceBiotech's Fierce 15 in 2017. For more information, please
visit www.aravive.com.
Contacts for Aravive:
Investors:
Christina Tartaglia
Stern Investor Relations
christina@sternir.com
Media:
Heidi Chokeir
Canale Communications
heidi@canalecomm.com
619-203-5391
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Apr 2023 to Apr 2024